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Abstract
Nonischemic cardiomyopathy is a collective term, encompassing a spectrum 
of cardiac comorbidities, accompanying the progressing end-stage liver disease. 
Alcoholic and cirrhotic cardiomyopathies are the most researched, well-known 
clinical entities in the list of nonischemic cardiac disorders that bear the most 
substantial impact on the clinical course, management, and outcomes of liver 
transplantation in ESLD patients. In this chapter, morphology, pathophysiology, 
diagnostic criteria, clinical manifestations, and management options of nonisch-
emic cardiomyopathy in liver transplant candidates and recipients, the patients with 
end-stage liver disease due to advanced stages of cirrhosis, are discussed.
Keywords: nonischemic cardiomyopathy, cirrhosis, liver transplantation, 
morphology, physiology, management
1. Introduction
The trend of performing liver transplants on an ever-increasing number of 
sicker patients with more severe cardio-vascular comorbidities, once considered as 
posing insurmountably high risk, prohibitive for surgery, is quickly becoming an 
everyday reality. Among other comorbidities, cardiomyopathies are considered as 
very common conditions that significantly alter the course of the liver disease and 
candidacy for liver transplant and contributes substantially to perioperative hemo-
dynamic profile and management and, eventually, to immediate and long-term 
outcome. While coronary artery disease-related morbidity remains the most serious 
concern in respect to liver transplant recipient well-being and outcomes, the groups 
of nonischemic cardiac conditions, that are increasingly common, oftentimes go 
underappreciated, underdiagnosed, and simply overlooked. The recent trends, 
however, demonstrate an increasing awareness and deeper understanding of these 
conditions.
Limited data is available about the actual prevalence of cardiomyopathy and 
its impact on the liver transplantation outcome. According to recent studies, it has 
been estimated that as many as 50% of patients undergoing liver transplantation 
developed at least some signs of cardiac dysfunction [1], and overall mortality from 
overt heart failure in the post liver transplantation period was estimated at about 
7–21% [2].
In this review, we will focus on physiological and clinical aspects of nonischemic 
cardiomyopathy, which accompany practically every liver disease in the advanced 
stages.
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Nowadays, the majority of transplant subspecialty physicians consider cardio-
myopathy mostly as either “cirrhotic” or “alcoholic,” with disregard to differences 
in physiology, clinical course and, for liver transplant recipients, even to outcome 
impact.
We suggest considering a “cardiomyopathy” as a collective term that refers to the 
spectrum of myocardial pathology, with a variety of etiological factors, ways and 
timing of development, similar, albeit not exactly identical, clinical manifestations, 
and degrees of contribution to hemodynamic profile of the liver transplant recipi-
ent. Furthermore, based on clinical features, cardiac morbidities, encountered in 
liver transplant candidates/recipients that qualify for nonischemic cardiomyopathy, 
may be divided into chronic forms (such as cirrhotic, alcoholic, etc.) and acute 
(stress-induced and Takotsubo).
In this review, we will focus on etiology, morphology, pathophysiology, diagnos-
tic criteria, and clinical manifestations of chronic nonischemic cardiomyopathies 
in liver transplant candidates. Acute nonischemic stress-induced cardiomyopathy 
discussion is beyond this chapter’s scope.
2. Etiology-related morphology
Etiologically different forms of cardiomyopathy have generally similar patho-
logical morphology and histopathology, with minimal, sometimes imperceptible, 
differences in microscopic details. In majority of cases, a histomorphological pic-
ture of nonischemic cardiomyopathy may be identified as having common features 
with chronic myocarditis, resulting in myocardial fibrosis, hypertrophic, dilated 
cardiomyopathy, or their combination.
As it has been demonstrated (using endomyocardial biopsy), a distinction 
between idiopathic, chronic inflammatory, and alcoholic cardiomyopathy is virtually 
impossible. Common features such as fibrosis, cardiac myocyte hypertrophy, and 
nuclear alterations have been observed in the alcoholic cardiomyopathy [3] or the 
World Heart Federation/International Society and Federation of Cardiomyopathy 
(WHF/ISFC) definition of myocarditis [4, 5]. Alcohol consumption is considered to 
be the major contributory factor of secondary nonischemic dilated cardiomyopathy 
in up to 33% of all cases of dilated cardiomyopathy [6, 7]. In alcoholic cardiomy-
opathy, dilation and impaired contraction of the left or both ventricles are observed 
[8]. Left ventricular end-diastolic diameters are increased compared to age- and 
weight-matched controls, the left ventricular mass index is increased, and the left 
ventricular ejection fraction is well below normal (<45%) [9].
Recent studies have demonstrated that Hepatitis C virus (HCV) also possesses 
tropism trait for other than liver tissues, such as lymphatic system and myocardial 
cell membranes. However, precise mechanisms of the myocardial damage have not 
yet been elucidated. Development of HCV-associated cardiomyopathy is considered 
as a result of multiple factors, such as viral, immunologic, and apoptotic-related in 
genetically susceptible patients [10]. Recent studies have demonstrated hepatitis C 
virus (HCV) involvement in the development of dilated cardiomyopathy, hyper-
trophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy in 
addition to myocarditis and myocardial fibrosis [11].
Cirrhotic cardiomyopathy is defined as “cardiac dysfunction in patients with 
cirrhosis, characterized by impaired contractile responsiveness to stress, diastolic 
dysfunction, and electrophysiological abnormalities in the absence of known 
cardiac disease” [12]. There is only very limited information about epidemiology, as 
well as actual prevalence of this condition at present time. Its diagnosis is difficult, 
because the majority of liver transplant candidates demonstrate nearly normal (for 
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cirrhotic patient) cardiac function at rest, and only during ESLD decompensation 
phases, they present with diastolic and/or high cardiac output heart failure [13]. 
However, QT interval prolongation in cirrhotic patients (25% in cirrhosis Child 
Pugh class A, 51% in Child Pugh class B, and 60% in Child Pugh class C) may be 
considered the earliest sign of cirrhotic cardiomyopathy; some information of 
prevalence might be derived from these data [14–16]. In earlier studies, cirrhotic 
cardiomyopathy has been considered to be related to both portal hypertension and 
cirrhosis itself, and is characterized by intrinsic alterations in myocardial function 
[17]. In its advanced stages, the morphology of cirrhotic cardiomyopathy may be 
described as, essentially, a combination of both dilated and hypertrophic cardiomy-
opathy, with various degrees of fibrosis development. Oftentimes, right- or bilateral 
atrial enlargement, along with right ventricle distension may be seen using TTE.
Hemochromatosis, due to iron deposition in myocardial cells, predisposes to 
either dilated or restrictive cardiomyopathy. If left untreated, hemochromatosis 
eventually progresses to end-stage heart and liver disease, with heart-liver trans-
plantation as the best treatment option [18]. Early electrocardiographic abnormali-
ties are frequent in patients with cirrhosis due to hemochromatosis. However, overt 
CHF is unusual [19]. Morphology of hemochromatosis-related cardiomyopathy 
in cirrhotic patients includes increased left ventricular mass, end-diastolic and 
end-systolic diameters of the left ventricle, and left atrium diameters, as well as 
significant changes of systolic function indices [20].
Nonalcoholic fat liver disease is becoming highly prevalent in the adult popula-
tion (15–30%), with increase to 70–90% in obesity and type 2 diabetes, represent-
ing one of the most common causes of chronic liver disease among LT candidates 
[21, 22]. The correlation between almost two-fold increased cardiovascular 
mortality and nonalcoholic steatohepatitis (NASH) has been clearly demonstrated 
[23]. Increased amounts of liver fat are associated with the presence of markers 
of inflammation and risk factors of coronary vascular disease, independent of 
BMI. Steatosis has been found to be the strongest independent risk predictor of 
vascular damage and also involved in pathogenesis of coronary vascular disease 
in liver transplant candidates. In a recent study, severe early LV diastolic and 
systolic dysfunctions were observed in NASH patients [24–26]. In a retrospective 
study, comparing patients with nonalcoholic steatohepatitis (NASH) and alcoholic 
cirrhosis, NASH was more frequently associated with cardiovascular events after 
liver transplant in comparison with that in the alcoholic cirrhotic patients [27, 28]. 
Although coronary artery disease and related ischemic cardiomyopathy is beyond 
the scope of this review, it seems worth mentioning the involvement of such com-
mon etiology of ESLD, such as NASH cirrhosis, in cardiomyopathy development.
3. Pathophysiology and mechanisms of nonischemic cardiomyopathy
3.1 Contractility impairment, systolic dysfunction, and diastolic dysfunction
Overall myocardial dysfunction physiology in cirrhotic patients is exceedingly 
complex, multicomponent, and still not entirely understood. Two main compo-
nents should be considered: myocardial contractility impairment and contribution 
of high cardiac output & low afterload hemodynamic profile (typical for ESLD 
patient hyperdynamic circulation), with secondary hemodynamic derangements, 
such as portopulmonary hypertension and related syndromes.
In their comprehensive review, Møller and Hendriksen [12] listed a number of 
potential mechanisms involved in the impairment of contractile function of the 
cardiomyocyte in cirrhotic cardiomyopathy on the receptor level. These include: 
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downregulation of b-adrenergic receptors with decreased content of G-protein, 
causing inotropic incompetency, and upregulation of cannabinoid 1-receptor 
stimulation; increased inhibitory effects of cardiodepressant substances such as 
hemoxygenase, carbon monoxide (CO), nitric oxide synthase (NOS)-induced nitric 
oxide (NO) release, and tumor necrosis factor-α( TNF – α). Many postreceptor 
effects are mediated by adenylyl cyclase inhibition or stimulation. Altered func-
tion and reduced conductance of potassium channels, inhibition of L-type calcium 
channels, and increased fluidity of the plasma membrane (increased cholesterol/
phospholipid ratio) also contribute to reduced calcium release and contractility.
It has been demonstrated that the reduced β - adrenergetic-dependent inotropic 
effect could be attributed to an overexpression of inhibitory G-protein and regula-
tors of G-protein signaling, which inhibit the adenylate cyclase, and those that 
accelerate degradation of cAMP such as phosphodiesterase [29]. The endogenous 
and exogenous cannabinoids exert mostly a vasodilatory effect. The ability of 
endocannabinoids to induce apoptosis of hepatic stellate cells, promoting the 
development of portal hypertension and hyperdynamic circulation, amplifies by 
vasodilation [30]. Increased local endocannabinoid production in cirrhosis and 
activation of CB1 receptors by endogenous anandamide contributes to the reduced 
cardiac contractility in cirrhosis [31].
Experimental evidence suggests that nitric oxide (NO) plays a significant role 
in the decreased vascular responsiveness to vasoconstrictors [32]. NO has been 
shown to cause significant impairment of the contractility in cirrhotic rats. Results 
of experimental studies have indicated that the cytokine–NO pathway occurs in 
cirrhotic rat hearts with enhanced expression of the NO synthase, and that inhibi-
tion of the NO synthesis by the NO inhibitor L-NAME reverses the impaired cardiac 
contractility [33–35].
Abnormalities in the properties of the plasma membrane determine the 
magnitude of the ion channel dysfunction. A decreased density of potassium cur-
rents in ventricular myocytes, which may contribute to prolong the QT interval, 
has been found on an experimental model. Also, a reduced expression and density 
of L-type Ca++ channels and inward cellular calcium current have been found 
as well, which may contribute to reduced contractility and also cause changes in 
excitation-contraction coupling and prolonged QT interval, with arrhythmogenic 
effect ensued [36–38].
B-type natriuretic peptide (BNP) and its prohormone, pro-BNP, are sensitive 
markers of even mild myocardial injury. Both compounds have been found elevated 
in patients with compensated and decompensated cirrhosis and seemingly correlate 
with the severity of cardiac dysfunction and myocardial hypertrophy [39, 40].
All aforementioned mechanisms of contractility impairment contribute to systolic 
dysfunction development. In majority of liver transplant candidates, the left ven-
tricular ejection fraction (LVEF), which serves as relatively integral index of systolic 
function assessment, has been found normal (EF of 50–60%) or increased (EF > 70%) 
at rest in patients with cirrhosis [41, 42]. Some attenuation of LVEF has been shown 
after exercise, sodium load, or erect posture [43]. Blunted heart rate response to stress, 
reduced myocardial reserve, and impaired muscular oxygen extraction are among rea-
sons that potentially contribute to the systolic dysfunction in cirrhotic patients [44].
Diastolic dysfunction is characterized by abnormal left ventricular relaxation, 
impeding blood flow through the ventricle, increasing left ventricular end-diastolic 
pressure, and increasing atrial contribution to late ventricular filling [45]. Diastolic 
dysfunction may be a consequence of either hypertrophic or dilated cardiomyopa-
thy, myocardial patchy fibrosis, and subendothelial edema [46]. The histopathology 
of diastolic dysfunction showed cardiomyocyte hypertrophy, altered pigmenta-
tion, interstitial fibrosis, and myofiber vacuolization [47]. Diastolic dysfunction, 
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manifesting in impaired passive and active filling of the left ventricle during 
diastole, causes an inability to adequately increase stroke volume in response to 
stress and other stimuli. Diastolic dysfunction may precede systolic dysfunction 
in cirrhosis [48]. The clinical significance of diastolic dysfunction has been best 
demonstrated in cases of rapidly developing heart failure after transjugular intra-
hepatic portosystemic shunts (TIPS) [49]. It has been found that after TIPS, there is 
an increase in the left atrial diameter, the pulmonary capillary wedge pressure, and 
total pulmonary resistance [50].
3.2 Role of the hyperdynamic circulation
As it has been shown in numerous studies, peripheral and splanchnic vasodilata-
tion appears to be the leading cause of hyperdynamic circulation in advanced stages 
of ESLD [51]. Initially, a reduction in systemic vascular resistance is compensated 
by an increase in cardiac output (almost to 200% of baseline), and effective circu-
lating blood volume satisfies the requirements for adequate peripheral perfusion. 
In advanced stages of cirrhosis, a further reduction in systemic vascular resistance 
cannot be compensated by a further increase in cardiac output, which leads to 
relative “hypovolemia” that manifests in hemodynamic instability and poor stress 
(e.g. blood loss) tolerance. At this stage, other mechanisms, such as activation of the 
renin-angiotensin system, sympathetic nervous system, and antidiuretic hormone 
overproduction, are employed to maintain effective circulating blood volume and 
perfusion pressure. Activation of these same compensatory systems is the leading 
cause of sodium and water retention and, ultimately, ascites formation [52, 53].
Though overt heart failure in even advanced stages of ESLD is a rare occurrence, 
the compensation mechanisms eventually are becoming overwhelmed, and, in a 
view of very limited myocardial reserve, already impaired contractility, systolic 
and diastolic dysfunctions, and myocardial performance are starting to decline 
substantially.
3.3 Role of portopulmonary hypertension
Portopulmonary hypertension is defined as pulmonary hypertension, associ-
ated with portal hypertension with or without accompanying liver cirrhosis. The 
correlation between development of portopulmonary hypertension and the severity 
of liver disease has not been found. Approximately 20% of candidates for liver 
transplantation will have elevated pulmonary artery pressures, but have a normal 
pulmonary vascular resistance (PVR). Such PA pressure increase may be the result 
of volume overload, cardiac failure, and high output circulation. True portopulmo-
nary hypertension has a prevalence of 5–6% among liver transplant candidates and 
is the result of pathological changes in the pulmonary vasculature [54].
In the assessment of a liver transplant candidate, presenting with portopulmonary 
hypertension, a right heart catheterization, a transthoracic echocardiography, and a 
test-challenge with volume bolus and dobutamine test are instrumental in determin-
ing the limits of patient’s tolerance for potential liver transplantation procedure [55].
The most important component of the porto-pulmonary syndrome physiol-
ogy is, actually, not so much the degree of pulmonary hypertension, expressed in 
pulmonary artery pressure figures, but rather right ventricle (RV) dysfunction, 
namely significant shape (i.e. RV dilation) and systolic function alterations. In the 
group of patients with more rapid increase in PAP (as opposed to the slow, gradual 
pulmonary hypertension development), early RV dilation and more significant 
pulmonary regurgitation, leading to various degrees of right ventricular failure and 
decompensation, have been found [56].
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Systolic dysfunction
1. Blunted increase in cardiac output on exercise, volume challenge, or pharmacological stimuli
2. Resting ejection fraction, 55%
Diastolic dysfunction
1. E/A ratio, 1.0 (age-corrected)
2. Prolonged deceleration time (0.200 ms)
Supportive criteria
1. Electrophysiological abnormalities:
• Abnormal chronotropic response
• Electromechanical uncoupling/dyssynchrony
• Prolonged Q–Tc interval
2. Enlarged left atrium
3. Increased myocardial mass
4. Increased BNP and pro-BNP
5. Increased troponin I
BNP, brain natriuretic peptide; E/A ratio, ratio of early to late (atrial) phases of ventricular filling (from: 46, with 
modifications).
Table 1. 
Diagnostic criteria of cirrhotic cardiomyopathy.
Portopulmonary hypertension has an enormous impact on liver transplantation 
outcome. A mean pulmonary artery pressure (MPAP) of 50 mm Hg or greater has 
been found to be associated with a 100% post-OLT mortality rate, and a MPAP of 35 
to <50 mm Hg is associated with a 50% post-OLT mortality rate [57]. For the time 
being, severe portopulmonary hypertension is considered to be an absolute contra-
indication to liver transplant. Patients with moderate severity should be considered 
for pulmonary vasodilator therapy, and their candidacy for liver transplantation 
depends on their hemodynamic response [58].
Liver transplantation may not reverse the portopulmonary hypertension. Long-
term vasodilator therapy may be necessary after the surgery, and, nevertheless, the 
syndrome may persist for years [59, 60].
It remains unclear, to which exact degree portopulmonary hypertension contrib-
utes to worsening of preexisting cardiomyopathy. However, its role in the develop-
ment of right ventricle dilation and ultimate right heart failure appears to be more 
significant than commonly recognized.
4. Diagnostic criteria
A proposal for diagnostic and supportive criteria for cirrhotic cardiomyopathy 
agreed upon at the 2005 World Congress of Gastroenterology in Montreal pub-
lished in 2008, a working definition of cirrhotic cardiomyopathy is formulated as 
 follows: “A cardiac dysfunction in patients with cirrhosis characterized by impaired 
contractile responsiveness to stress and/or altered diastolic relaxation with electro-
physiological abnormalities in the absence of other known cardiac diseases.” The 
diagnostic criteria are summarized in Table 1.
While systolic dysfunction ECO-diagnosis is more or less straightforward, 
diastolic dysfunction sometimes presents a certain challenge. TTE/TEE diagnostic 
criteria of diastolic dysfunction include decreased ratio of early to late atrial phases 
of ventricular filling (E/A ratio, less than 1). The decreased E/A ratio is a relatively 
common finding in cirrhotic patients [43, 61
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wave (E′) is considered a more accurate marker for evaluation of diastolic dysfunc-
tion, due to its decreased dependency on the preload in the presence of diastolic 
dysfunction. With worsening of the diastolic dysfunction, the E′ decreases, which 
reflects the increased stiffness of the ventricle. The E:E′ ratio has been found to 
reflect left ventricular filling pressure, and this ratio increases as diastolic function 
worsens [62–65].
5. Clinical manifestations and reversibility
The clinical manifestations of cirrhosis-related myocardial dysfunction are 
becoming evident during liver transplantation surgery, when the hemodynam-
ics are affected by numerous factors that include blood loss and fluid shifts with 
substantial third space formation, mechanical ventilation, large vessel clamping 
(specifically portal vein and IVC), and effects of anesthesia. In severe cases, heart 
failure manifests in significant reduction in the cardiac output [66, 67]. The prob-
lem is that, considering the baseline abnormally increased CO (up to 10–12 L/min), 
a gradual decrease to 4–5 L/min may not be immediately perceived as such and 
interpreted as a sign of ongoing myocardial decompensation. In the clinical study 
on 209 liver transplant recipients, abnormal cardiac response was observed in 47 
(22.5%) patients after reperfusion. The authors suggested that the abnormal cardiac 
response observed during liver transplantation is a manifestation of occult cirrhotic 
cardiomyopathy [68].
A number of factors affect myocardial performance in the immediate postopera-
tive period. Persisting metabolic disturbances, specifically lactic acidosis, hypother-
mia, and electrolyte disturbances (hyperkalemia and hypocalcemia) can further 
compromise cardiac performance. Among multiple causes of postoperative hemo-
dynamic instability (such as underestimated hypovolemia due to ongoing or occult 
hemorrhage, third space formation/losses), a preexisting dilated cardiomyopathy 
should not be overlooked.
The rapid improvement of systemic vasodilatation, especially in combination 
with use of vasoactive agents, can result in a sudden increase in the afterload, 
which is another possible cause of excessive myocardial stress, leading to potential 
development or worsening of the existing heart failure. It has been found that after 
liver transplantation, almost 25% of liver transplant recipients have cardiovascular 
complications and an increased risk for postoperative pulmonary edema [16]. 
Postoperative pulmonary edema is quite common occurrence, and at least 50% of 
edema episodes develop within the first 24 h after surgery [69].
Reversibility of cardiomyopathy after liver transplant, albeit previously pre-
sumed very likely, appears to be not all that assured, let alone guaranteed, according 
to recent clinical studies. In the retrospective study on 243 liver transplant recipi-
ents, the diastolic dysfunction and QT interval changes have been investigated in 
postoperative period. The results revealed that the grade of diastolic dysfunction 
significantly worsened on echo performed after transplantation. Diastolic function 
worsened in up to 40% of the patients. Furthermore, longer QT was indepen-
dently associated with adverse outcomes after OLT. Although QT significantly 
decreased after OLT, prolonged QT continued to be prevalent among patients after 
OLT. However, as study demonstrated that despite being associated with a longer 
hospital stay, the presence of diastolic dysfunction was not independently associ-
ated with long-term adverse outcomes after OLT. The authors concluded that some 
parameters, representing cirrhotic cardiomyopathy, such as diastolic dysfunction 
and prolongation of QT, continued to worsen or, at least persist in patients for many 
years after OLT [70].
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6. Management: possible treatment options
Universally accepted treatment for clinically significant cardiomyopathy is 
yet to be established. Pharmacological interventions should be directed at the 
most important components of the syndrome, such as systolic and diastolic 
dysfunction, electrophysiological abnormalities, and impaired contractility. 
Liver transplant remains an ultimate cure for cirrhosis and for its major compli-
cations; it is also likely to cure the cirrhotic cardiomyopathy. However, neither 
time frame nor the extent of myocardial functional and structural recovery is 
known yet.
Nonselective β-blockers have been shown to improve the prolonged QT interval; 
β-blockers-induced cardiac output modification/reduction might play a positive 
role in the reduction of the hyperdynamic load [71, 72].
The common principles of the congestive heart failure treatment are completely 
applicable and should be followed, once heart failure manifests in liver transplant 
recipient. Depending on renal function (or lack thereof, in cases of severe hepa-
torenal syndrome or acute kidney injury), the treatment of CHF in cirrhotic patient 
will, most likely, include diuretics. It is likely, that patients with manifesting heart 
failure also exhibit a diuretic-resistant ascites. Even in these cases, aldosterone 
antagonists, such as spironolactone, might be beneficial in reducing left ventricular 
hypertrophy and dilatation, potentially improving diastolic dysfunction [73]. 
The known effects of aldosterone, such as myocardial fibrosis development, and 
baroreceptor dysfunction, provide a rationale for using an aldosterone antagonist, 
to counteract these effects [74].
The most significant hemodynamic instability, occurring during liver transplan-
tation surgery, may be partially attributed, among other well-recognized factors 
(such as inherently low Systemic Vascular Resistance (SVR), to the manifestation or 
exacerbation of myocardial dysfunction due to preexiting cardiomyopathy.
At the start of the anhepatic stage, the portal cross clamp causes a variable 
(20–30% of baseline) degree of venous return decrease. IVC complete cross-clamp 
oftentimes leads to a more substantial and poorer tolerated (approximately 50%) 
decrease of venous return, whereas IVC partial clamp causes a variable, about 
25–50%, decrease of venous return [75]. This rapid decrease in preload may be tol-
erated poorly by patients with ESLD. These patients have notoriously very limited 
ability, if any, to compensate for the rapid decrease in venous return with systemic 
vasoconstriction, due to inherent low SVR.
The possible solution to compensate, at least temporarily, for the decreased 
venous return (thus drop in cardiac output, which becomes substantially more 
pronounced in patients with both systolic and diastolic dysfunctions) is a venove-
nous bypass (VVB). It has been suggested that hypotension (30% decrease in MAP) 
or a decrease in cardiac index (50%) during a 5-min test period of hepatic vascular 
occlusion can be used to identify the group of patients, who require VVB. Other 
indications to the VVB include the presence of pulmonary hypertension, impaired 
ventricular function from previous myocardial infarction, ischemic heart disease, 
and cardiomyopathy [76, 77].
In patients with pulmonary hypertension (either idiopathic or due to portpul-
monary syndrome), excessive fluid loading to compensate for hypovolemia-related 
hemodynamic instability may result in acute right ventricular dysfunction. Patients 
with preexisting cardiomyopathy, mostly impaired left ventricular function, 
express a limited ability to generate an adequate CO. These patients, too, may 
benefit from the ameliorative effect of the preload, associated with VVB, through-
out the whole of liver transplant surgery, but particularly during anhepatic and 
postreperfusion stages [67].
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In the view of rapid hemodynamic changes, associated with IVC either complete 
or even partial clamps, large amounts of fluids, along with blood products, are 
often needed to be administered. In patients with impaired renal function (ranging 
from acute kidney injury to hepatorenal syndrome and end-stage renal disease, 
intraoperative dialysis is used, mostly for the purposes of renal function complete 
replacement or preservation. Hemodialysis is also very efficient means of intravas-
cular volume regulation, specifically in elimination of fluid overload [78]. These 
properties make hemodialysis and hemofiltration valuable and efficient tools also 
in decreasing a burden on dysfunctional myocardium, particularly in patients with 
substantial diastolic dysfunction due to cardiomyopathy. The target is to achieve 
euvolemia or a zero balance ultrafiltration volume by the use of hemodialysis, which 
becomes especially beneficial after IVC unclamping, the very intraoperative event, 
that causes notoriously substantial right ventricle volume overload, with potential 
to decompensation in cases of advanced cardiomyopathy [79].
Graft reperfusion and postreperfusion syndrome presents the most significant 
challenge for hemodynamic management, especially in patients with severe car-
diomyopathy. Different drug combinations have been tested and recommended 
for rapid hemodynamic recovery after liver graft reperfusion. Vasopressin in 
small boluses, 1–2 U, may be highly efficient in opposing the significant and rapid 
decrease of SVR, and calcium chloride, up to 1000 mg, may enhance inotropic 
effects of epinephrine [67, 80]. Methylene blue, 2 mg/kg, has been reported as very 
efficient and “last resort” drug for prolong and profound hypotension, refractory to 
treatment with other vasoactive drugs [81]. The immediate hemodynamic stabiliza-
tion (on the face of severely compromised myocardial function, in combination 
with rapid decrease in SVR, observed during postreperfusion stage), which all 
these drug combinations provide, should be further maintained with continuous 
infusion administration of vasoactive agents, such as phenylephrine or vasopres-
sin, targeting primarily reduction of systemic vascular resistance. Compromised 
myocardial performance due to preexisting dilated cardiomyopathy and especially 
its worsening after graft reperfusion oftentimes necessitates addition of agents with 
β-adrenergic activities, such as norepinephrine, and, rarely, epinephrine [82, 83].
To better understand the causes and mechanisms of blunted cardiac response to 
stress and inotropic incompetence, investigations on the gene expression pattern of 
the cardiomyocyte adrenergic pathway in animal models of cirrhosis are underway 
[84]. New gene-targeting pharmacological strategies, based on the findings of these 
studies, might be the future direction of the cardiomyopathy treatment, and also, of 
course, a promising new direction of the research.
The normalization of cardiac function after liver transplantation is still a 
likely and attainable goal in majority of cases, provided all treatment modalities 
are employed in full and timely manner, and, above all, the liver transplantation 
procedure is successful.
7. Conclusions
The term “nonischemic cardiomyopathy” represents a spectrum of cardiac 
comorbidities, encountered in the liver transplant recipient at every stage of the pro-
cess, namely, in preoperative period, intraoperatively, and during recovery. Alcoholic 
and cirrhotic cardiomyopathies are the well-known clinical entities. Yet, oftentimes, 
these conditions remain unrecognized and underdiagnosed in clinical setting.
Morphology of nonischemic cardiomyopathy includes various anatomical 
derangements, ranging from right and/or left atrial enlargement/distention to 
severe ventricular dilation and constrictive changes, with correspondent profound 
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physiological effects that include significant diastolic, followed by systolic, 
dysfunction and eventually resulting in the frank heart failure. Rhythm distur-
bances are very common, and serve as an early diagnostic sign of the developing 
cardiomyopathy.
To date, a consensus on causes, physiological mechanisms, and, most impor-
tantly, management and treatment of nonischemic cardiomyopathy is yet to be 
achieved. The existing management and treatment modalities are directed mostly 
on hemodynamic optimization at every stage of the transplantation process, and 
remain extremely complex and challenging intraoperatively, when a clinician faces 
multilevel surgery-related hemodynamic derangements, exacerbated greatly by the 
presence of clinically significant cardiomyopathy.
Decades of experience has shown that at least complete hemodynamic recovery, 
if not a meaningful structural and functional restoration of the myocardium, is an 
achievable goal in liver transplant recipients, and recent studies in this particular 
field have achieved promising results.
Further research on physiology, genetics, and treatment options is warranted, 
and results of multicenter studies, involving large numbers of liver transplant 
recipients, are much needed to be implemented to ensure successful outcome of 
liver transplantation in recipients, suffering from nonischemic cardiomyopathy.
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